Barcelona, November 2nd, 2021.- VCN Biosciences, a clinical-stage immuno-oncology company focused on the development of the next generation of oncolytic adenoviruses, today announced the oral presentation at the upcoming 2021 International Oncolytic Virus Conference (IOVC) being held November 5-7, 2021, both virtually and in Sedona, Arizona.
Miriam Bazan Peregrino, DPhil (Oxon), R&D Director of VCN Biosciences SL, will be presenting VCN Biosciences latest results of the Clinical Trial of VCN-01 against retinoblastoma (ClinicalTrials.gov Identifier: NCT03284268):Miriam Bazan Peregrino, DPhil (Oxon), R&D Director of VCN Biosciences SL, will be presenting VCN Biosciences latest results of the Clinical Trial of VCN-01 against retinoblastoma (ClinicalTrials.gov Identifier: NCT03284268):
“Oncolytic Adenovirus VCN-01 Targeting the Dysfunctional Rb Pathway Is an Encouraging Therapy Against Retinoblastoma”
International Oncolytic Virus Conference 2021Scientific Session 9: Clinical Trials 37th November 202111:44-11:56 a.m. (GMT-7).
About VCN Biosciences
VCN Biosciences is a clinical-stage immuno-oncology company focused on the development of the next generation of oncolytic adenoviruses. VCN candidates are designed to obtain clinical activity after systemic administration and are able to remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences lead product, VCN-01, is a oncolytic adenovirus with unique characteristics being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. For more information, please visit www.vcnbiosciences.com.